Clinical impact of serum soluble SLAMF7 in multiple myeloma-Reference-Cited by-同舟云学术

Clinical impact of serum soluble SLAMF7 in multiple myeloma

Published:2018-10-05 Issue:78 Volume:9 Page:34784-34793
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Ishibashi Mariko¹²,Soeda Saori¹,Sasaki Makoto³,Handa Hiroshi⁴,Imai Yoichi⁵,Tanaka Norina⁶,Tanosaki Sakae⁷,Ito Shigeki⁸,Odajima Takeshi⁹,Sugimori Hiroki¹⁰,Asayama Toshio¹,Sunakawa Mika¹,Kaito Yuta¹,Kinoshita Ryosuke¹,Kuribayashi Yasuko¹,Onodera Asaka¹,Moriya Keiichi¹,Tanaka Junji⁶,Tsukune Yutaka³,Komatsu Norio³,Inokuchi Koiti¹,Tamura Hideto¹

Affiliation:

1. Department of Hematology, Nippon Medical School, Tokyo, Japan

2. Department of Microbiology and Immunology, Nippon Medical School, Tokyo, Japan

3. Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan

4. Department of Hematology, Gunma University, Gunma, Japan

5. Department of Hematology and Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

6. Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan

7. Department of Hematology, The Fraternity Memorial Hospital, Tokyo, Japan

8. Department of Clinical Oncology, Iwate Medical University School of Medicine, Iwate, Japan

9. Faculty of Health Science, Daito Bunka University Graduate School of Sports and Health Science, Tokyo, Japan

10. Department of Preventive Medicine, Daito Bunka University Graduate School of Sports and Health Science, Saitama, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies;Current Opinion in Oncology;2024-06-19

2. A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers;International Journal of Molecular Sciences;2024-06-15

3. Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma;The Lancet Haematology;2024-02

4. Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE;Blood;2023-11-23

5. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments;Current Oncology;2023-08-27